| Name | Title | Contact Details |
|---|
Family HealthCare Network is a private nonprofit organization that operates 20 sites, 16 of which are federally qualified health centers located throughout Tulare and Kings Counties. Our mission is to provide quality health care to everyone in the communities we serve. With more than 160 medical and dental providers in our network, we provide access to a wide range of coordinated health services. FHCN also offers pharmacy services, free transportation, and extended evening and weekend hours. FHCN is recognized by the National Committee for Quality Assurance (NCQA) as a Level 3 Patient Centered Medical Home and is dually recognized by The Joint Commission with its Gold Seal of Approval® for Patient Quality and Safety and as a Patient Centered Primary Medical Home.
NarrativeDx is the artificial intelligence platform for patient experience. Our SaaS platform is the market leader in transforming hospitals` clinical outcomes by extracting data trends and gaining visibility into the patient experience. We help hospital leaders and care providers understand and improve their institution`s patient experience, drive patient referrals, increase hospital revenue, and boost hospital reputations.
Goode Consulting Intl is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Acusis is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.